National LymphoCare Study survey of current practice for FL in the United States
| Treatment . | Frequency, % . |
|---|---|
| Watch and wait | 19 |
| Rituximab monotherapy | 13 |
| Chemoimmunotherapy | 51 |
| R-CHOP | 59 |
| R-CVP | 19 |
| R-fludarabine based | 11 |
| R-other | 11 |
| Chemotherapy alone | 4 |
| Radiation alone | 5 |
| Treatment . | Frequency, % . |
|---|---|
| Watch and wait | 19 |
| Rituximab monotherapy | 13 |
| Chemoimmunotherapy | 51 |
| R-CHOP | 59 |
| R-CVP | 19 |
| R-fludarabine based | 11 |
| R-other | 11 |
| Chemotherapy alone | 4 |
| Radiation alone | 5 |
R-CHOP indicates rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CVP, rituximab, cyclophosphamide, vincristine, and prednisone.